Effective Analgesic Score: A "Marker" of the Effects of Chemotherapy on Pain in Advanced Cancer Patients?

Journal of Pain and Symptom Management

Volumn 34, Issue 4, 2007, Pages 339-342

  Porzio, Giampiero ^a   Aielli, Federica ^a   Verna, Lucilla ^a   Shodia E Razavi, Ghazaleh ^a   Tudini, Marianna ^a   Cannita, Katia ^a   Ficorella, Corrado ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BUPRENORPHINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIRUBICIN; FENTANYL; FLUOROURACIL; GABAPENTIN; GEMCITABINE; IRINOTECAN; KETOROLAC; MORPHINE; NIMESULIDE; OXALIPLATIN; PACLITAXEL; TRASTUZUMAB;

ADVANCED CANCER; ANALGESIA; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; HUMAN; LETTER; LIPOSARCOMA; LUNG CANCER; MELANOMA; OVARY CANCER; PAIN ASSESSMENT; PANCREAS CANCER; PROSTATE CANCER; RATING SCALE; RECTUM CANCER; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PAIN; PAIN MEASUREMENT; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TERMINAL CARE; TREATMENT OUTCOME;

EID: 34548839383     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2007.05.005     Document Type: Letter

References (8)

1. Mercadante S. Scoring the effect of radiotherapy for painful bone metastases. Support Care Cancer 14 (2006) 967-969
2. Bottomley A., Gaafa R., Manegold C., et al. Short treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung Cancer Group and National Cancer Institute, Canada, Intergroup Study. J Clin Oncol 24 (2006) 1435-1442
3. Vansteenkiste J.F., Vanderbroek J.E., Nackaerts K.L., et al. Clinical-benefit response in advanced non-small-cell lung cancer: a multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol 12 (2001) 1221-1230
4. Fossà S.D., Slee P.H., Brausi M., et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European Organization for Research and Treatment of Cancer Genitourinary Group. J Clin Oncol 19 (2001) 62-71
5. Beer T.M., Eilers K.M., Garzotto M., et al. Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate cancer. Cancer 15 (2004) 758-763
6. Berry D.L., Moinpour C.M., Jiang C.S., et al. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 24 (2006) 2828-2835
7. Ernst D.S., Tannock I.F., Winquist E.W., et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 21 (2003) 3335-3342
8. Morant R., Bernhard J., Maibach R., et al. Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Ann Oncol 11 (2000) 183-188